News

The update on this clinical study could influence BioNTech’s stock performance by potentially boosting investor confidence if the results are favorable. The involvement of collaborators like ...
The intervention being tested is BNT327, administered in two dose levels, combined with standard chemotherapy drugs such as etoposide, carboplatin, paclitaxel, and topotecan. The purpose is to ...
The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.
Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human Services, has ...
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...
Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...
Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.
“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...
The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...
Stocks in the health-care industry rose as markets grew more confident that U.S. borrowing costs will fall, while companies in the sector pleased investors in their quarterly reports. Gilead Sciences ...
26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth ...
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...